Research output per year
Research output per year
Search results
-
2023
BT8009-100: A phase I/II study of novel bicyclic peptide and MMAE conjugate BT8009 in patients (pts) with advanced malignancies associated with nectin-4 expression, including urothelial cancer (UC).
Baldini, C., Goldschmidt, V., Brana, I., Doger, B., Italiano, A., Cousin, S., Falchook, G. S., Necchi, A., Reig, O., Carter, L., Fontana, E., Verlingue, L., Hazard, S., Dickson, A., Xu, C., Xu, H., Sharma, R., Smethurst, D. & McKean, M., 21 Feb 2023, p. 498-498. 1 p.Research output: Contribution to conference › Abstract › peer-review
-
2022
5MO Comprehensive dose-finding strategy for single-agent RP-3500, a highly selective inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase
Fontana, E., Lee, E., Rosen, E., Spigel, D., Højgaard, M., Lheureux, S., Mettu, N. B., Carter, L., Plummer, R., Manley, P., Ulanet, D., Rimkunas, V., Silverman, I. M., O'Connell, J., McDougall, R., Wainszelbaum, M., Xu, Y., Koehler, M., Fretland, A. J. & Yap, T. A., Mar 2022, p. S3-S4.Research output: Contribution to conference › Abstract › peer-review
-
Abstract CT030: Genomic and pathologic determinants of response to RP-3500, an ataxia telangiectasia and Rad3-related inhibitor (ATRi), in patients (pts) with DNA damage repair (DDR) loss-of-function (LOF) mutant tumors in the Phase 1/2 TRESR trial
Yap, T. A., Silverman, I. M., Fontana, E., Lee, E., Spigel, D., Højgaard, M., Lheureux, S., Mettu, N., Carneiro, B. A., Carter, L., Plummer, R., Schonhoft, J. D., Ulanet, D., Nejad, P., Manley, P., Reis-Filho, J. S., Xu, Y., Rimkunas, V., Koehler, M. & Rosen, E., 15 Jun 2022, p. CT030-CT030.Research output: Contribution to conference › Abstract › peer-review
-
2021
Abstract CC04-01: First-in-human biomarker-driven phase I TRESR trial of ataxia telangiectasia and Rad3-related inhibitor (ATRi) RP-3500 in patients (pts) with advanced solid tumors harboring synthetic lethal (SL) genomic alterations
Yap, T., Lee, E., Spigel, D., Fontana, E., Højgaard, M., Lheureux, S., Mettu, N. B., Carter, L., Plummer, R., Ulanet, D., Manley, P., Jiang, Y. & Rosen, E., 1 Dec 2021, p. CC04-01-CC04-01.Research output: Contribution to conference › Abstract › peer-review
-
A real-world analysis of 30-day post systemic anti-cancer therapy mortality in patients with small cell lung cancer
Carter, L., Church, M. & Blackhall, F., Jun 2021.Research output: Contribution to conference › Abstract › peer-review
-
2020
Outcome of molecular profiling of sarcoma patients referred to an early phase clinical trial unit
Lowe, J., Nutman, C., Dransfield, J., Rothwell, D., Thistlethwaite, F., Cook, N., Graham, D., Brady, G., Wallace, A. J., Dive, C., Krebs, M. & Carter, L., 2020.Research output: Contribution to conference › Abstract › peer-review
-
2019
A first-in-human phase I/II trial of SRA737 (a Chk1 Inhibitor) in subjects with advanced cancer.
Plummer, E. R., Kristeleit, R. S., Cojocaru, E., Haris, N. M., Carter, L., Jones, R. H., Blagden, S. P., Evans, T. R. J., Arkenau, H.-T., Sarker, D., Danson, S., Symeonides, S. N., Walter, H., Ocen, J., Randhawa, M., Kowalski, M. M., Verdon, I., Dye, A. & Banerji, U., 2019, p. 3094-3094. 1 p.Research output: Contribution to conference › Abstract › peer-review
-
A phase I/II first-in-human trial of oral SRA737 (a Chk1 inhibitor) given in combination with low-dose gemcitabine in subjects with advanced cancer.
Banerji, U., Plummer, E. R., Moreno, V., Ang, J. E., Quinton, A., Drew, Y., Hernández, T., Roda, D., Carter, L., Navarro, A., Kristeleit, R. S., Arkenau, H.-T., Sarker, D., Castellano, D. E., Walter, H., Roxburgh, P., Blagden, S. P., Anthoney, A., Verdon, I. & Jones, R. H., 2019, p. 3095-3095. 1 p.Research output: Contribution to conference › Abstract › peer-review